Cerus Corporation (NSDQ:CERS) said today that it exercised $10.8 million in additional options from its contract with the Biomedical Advanced Research & Development Authority, a part of the U.S. Dept. of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. The funds will go towards in vitro pathogen inactivation and red blood cell function studies in support of FDA licensure and manufacturing clinical trial materials for a phase III trial in the U.S.
Concord, Calif.-based Cerus is developing the Intercept blood system, a pathogen reduction device designed to inactivate a broad range of viruses, bacteria, parasites and leukocytes in donated blood.
Get the full story at our sister site, Drug Delivery Business News.
The post Cerus raises funds for phase III trial of Intercept red blood cell system appeared first on MassDevice.
from MassDevice http://ift.tt/2h4tPRq
Cap comentari:
Publica un comentari a l'entrada